EGF and EGF receptor (EGFR) are aberrantly expressed in both androgen-independent and metastatic prostate cancers, with high EMT-related features, and are strongly associated with an aggressive phenotype, a poor clinical prognosis, a high Gleason score, and a reduced survival rate [263]. Here, EGF is linked to Familial prostate cancer.